pulmonologyadvisor16d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
HealthDay News — The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
Renal & Urology News21d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog administered subcutaneously 5 to 10 minutes before mealtime helps improve glycemic control. (HealthDay News) — The US Food and Drug Administration has approved Merilog (insulin-aspart ...
clinicalpainadvisor.com21d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...
WebMD21d
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.
healthday22d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
Managed Healthcare Executive23d
FDA Approves First Biosimilar of Novolog
Novo Nordisk’s NovoLog has a list prices of $139.71 for FlexPen, $72.34 for 10 mL vial, and $134.37 for a PenFill Cartridge. Patients with commercial insurance whose coverage includes NovoLog may pay ...
Interesting Engineering23d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...
FiercePharma23d
FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog
The agency has given a thumbs up to Sanofi’s Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk’s NovoLog for patients with diabetes. Insulin aspart is delivered by a ...
Daily24d
Sanofi's Merilog Receives USFDA Approval as Biosimilar to Novolog for Diabetes Management
New Delhi: Sanofi has received U.S. Food and Drug Administration (FDA) approval for Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults ...
Medscape24d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.
Pharm Exec25d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The regulatory ...